Savara (SVRA)
NASDAQ:SVRA
Want to see SVRA full AI Analyst Report?
SVRA Stock Chart & Stats
$5.78
$0.04(1.15%)
At close: 4:00 PM EST
$5.78
$0.04(1.15%)
Day’s Range― - ―
52-Week Range$1.98 - $7.01
Previous CloseN/A
Volume189.20K
Average Volume (3M)1.31M
Market Cap
$1.08B
Enterprise Value$1.06B
Total Cash (Recent Filing)$202.77M
Total Debt (Recent Filing)$30.07M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding204,927,220
10 Day Avg. Volume1,464,480
30 Day Avg. Volume1,312,908
Financial Highlights & Ratios
PEG Ratio-1.08
Price to Book (P/B)6.60
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.15K
Enterprise Value/Ebitda-7.93
Forecast
1Y Price Target
$11.17Price Target Upside93.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.54
Revenue Forecast (FY)$3.18M
Bulls Say, Bears Say
Bulls Say
Positive Phase 3 Molgramostim Efficacy DataPhase 3 biomarker and DLco improvements are durable evidence of clinical effect in the lead program for autoimmune PAP. Positive pivotal data materially raises the program's probability of regulatory approval and strengthens long-term commercial potential in a definable orphan respiratory niche.
Focused Rare Respiratory Disease FranchiseA concentrated business model targeting rare pulmonary disorders creates structural advantages: clearer clinical endpoints, orphan incentives, and specialized commercialization pathways. This focus supports efficient R&D prioritization and potential pricing power in small, durable patient populations.
Manageable Leverage Relative To EquityLow reported debt relative to equity provides financial flexibility to fund ongoing clinical programs without large interest burdens. This structural balance-sheet strength lengthens runway compared with highly leveraged peers, easing operational continuity while development milestones are pursued.
Bears Say
No Revenue And Widening LossesThe company remains pre-revenue with materially increasing net losses, indicating operations are not yet self-sustaining. Sustained negative earnings erode capital and increase reliance on external financing, raising dilution and compromising strategic optionality if financing conditions tighten.
Accelerating Cash Burn And Negative Free Cash FlowRising operating cash outflows show that losses translate into real cash consumption rather than non-cash charges. The accelerating burn reduces runway and forces near-term capital raises, which can dilute shareholders and divert management focus from long-term development priorities.
Declining Equity And Capital Erosion RiskFalling shareholders' equity and negative ROE reflect cumulative losses depleting capital. Continued capital erosion narrows financial resilience against clinical setbacks, raises the cost and frequency of future financings, and limits strategic flexibility over the medium term.
Savara News
SVRA FAQ
What was Savara’s price range in the past 12 months?
Savara lowest stock price was $1.98 and its highest was $7.00 in the past 12 months.
What is Savara’s market cap?
Savara’s market cap is $1.08B.
When is Savara’s upcoming earnings report date?
Savara’s upcoming earnings report date is Aug 06, 2026 which is in 63 days.
How were Savara’s earnings last quarter?
Savara released its earnings results on May 12, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.135 by -$0.015.
Is Savara overvalued?
According to Wall Street analysts Savara’s price is currently Undervalued.
Does Savara pay dividends?
Savara does not currently pay dividends.
What is Savara’s EPS estimate?
Savara’s EPS estimate is -0.14.
How many shares outstanding does Savara have?
Savara has 204,927,220 shares outstanding.
What happened to Savara’s price movement after its last earnings report?
Savara reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.135. Following the earnings report the stock price went up 3.74%.
Which hedge fund is a major shareholder of Savara?
Currently, no hedge funds are holding shares in SVRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Savara Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.17 (93.19% Upside)
$11.17 (93.19% Upside)
Blogger Sentiment
Bullish
SVRA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 15.4%
Last 30 Days ▲ 15.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
118.75%
12-Months-Change
Fundamentals
Return on Equity
-87.19%
Trailing 12-Months
Asset Growth
17.08%
Trailing 12-Months
Company Description
Savara
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
SVRA Stock 12 Month Forecast
Average Price Target
$11.17
▲(93.19% Upside)
Technical Analysis
Ownership Overview
3.07% Insiders
7.45% Mutual Funds
74.40% Other Institutional Investors
4.43% Public Companies and
Individual Investors